SLS

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Sellas Life Sciences Group Inc

NASDAQ | SLS

2.00

USD

+$0.00

(

+0.00%

)

At Close (As of Oct 13, 2025)

$249.97M

Market Cap

-

P/E Ratio

-0.3

EPS

$2.27

52 Week High

$0.77

52 Week Low

HEALTHCARE

Sector

SLS Chart

Recent Chart
Price Action

SLS Technicals

Tags:

SLS Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$32M
Selling General And Administrative $12M
Research And Development $19M
Operating Expenses $32M
Investment Income Net -
Net Interest Income $632K
Interest Income $632K
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $32M
Income Before Tax -$31M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$31M
Comprehensive Income Net Of Tax -
Ebit -$62M
Ebitda -$31M
Net Income -$31M

Revenue & Profitability

Earnings Performance

SLS Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $19M
Total Current Assets $16M
Cash And Cash Equivalents At Carrying Value $14M
Cash And Short Term Investments $14M
Inventory -
Current Net Receivables -
Total Non Current Assets $3.1M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill $1.9M
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $2.3M
Other Non Current Assets -
Total Liabilities $10M
Total Current Liabilities $9.5M
Current Accounts Payable $3.5M
Deferred Revenue -
Current Debt -
Short Term Debt $1.1M
Total Non Current Liabilities $457K
Capital Lease Obligations $1M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $1M
Other Current Liabilities $4.9M
Other Non Current Liabilities -
Total Shareholder Equity $9.5M
Treasury Stock -
Retained Earnings -$248M
Common Stock $7K
Common Stock Shares Outstanding $612M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$35M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization -
Capital Expenditures $0
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -
Cashflow From Financing $47M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$31M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$32M
Selling General And Administrative $12M
Research And Development $19M
Operating Expenses $32M
Investment Income Net -
Net Interest Income $632K
Interest Income $632K
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $32M
Income Before Tax -$31M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$31M
Comprehensive Income Net Of Tax -
Ebit -$62M
Ebitda -$31M
Net Income -$31M

SLS News

SLS Profile

Sellas Life Sciences Group Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

SELLAS Life Sciences Group Inc. is an advanced-stage biopharmaceutical company headquartered in New York, dedicated to developing innovative cancer immunotherapies aimed at addressing a range of oncological indications. With a strategic focus on harnessing the body's immune system to target and fight cancer, Sellas is actively advancing its proprietary pipeline to meet the urgent needs of patients. The company’s commitment to transforming cancer treatment positions it as a key player in the evolving biopharmaceutical landscape.

VHAI
+66.66%
$0.00
YYAI
-10.47%
$0.17
BURU
+7.74%
$0.51
CGBS
-39.47%
$0.03
ELBM
+325.45%
$7.02
PLUG
+14.03%
$3.90
RGTI
+25.02%
$54.91
GWH
+117.54%
$9.05
BITF
+28.33%
$5.39
NVDA
+2.81%
$188.32
NVTS
+21.14%
$9.97
ASST
-30.54%
$1.08
IONZ
-32.55%
$2.29
BYND
-48.50%
$1.03
INTC
+2.33%
$37.22
JOBY
+3.00%
$16.77
DNN
+6.94%
$3.08
GPUS
-10.39%
$0.43
CAN
+39.44%
$1.52
QBTS
+23.01%
$40.61
TSLA
+5.41%
$435.90
BBD
+0.98%
$3.09
F
+1.13%
$11.54
CLF
+4.93%
$13.83
AXDX
-61.36%
$0.03
NIO
+7.00%
$7.18
QS
+15.57%
$16.98
AMD
+0.70%
$216.42
SOFI
+3.62%
$27.14
CRML
+55.40%
$23.28
ETHD
-12.82%
$3.33
CIFR
+19.85%
$20.34
ACHR
+6.68%
$12.77
RXRX
+3.94%
$5.53
APLD
+0.73%
$34.24
SOUN
+10.25%
$19.14
DFLI
+44.03%
$1.57
TLRY
-1.74%
$1.69
BTBT
+6.38%
$4.00
NAK
+31.03%
$2.66
LAES
+13.30%
$6.13
ONDS
+17.24%
$10.81
DVLT
-10.52%
$1.70
RR
+8.95%
$6.45
MP
+21.34%
$95.06
USAR
+18.61%
$38.68
IONQ
+16.19%
$82.09
IREN
+7.31%
$64.14
AVGO
+9.87%
$356.70
UAMY
+36.85%
$16.71
ABAT
+36.59%
$9.22
PFE
-0.20%
$24.73
SNAP
+3.47%
$8.05
NAKA
-1.56%
$0.85
RIG
+3.89%
$3.20
AAL
+1.90%
$11.74
QUBT
+12.85%
$21.46
UUUU
+16.86%
$23.77
MARA
+8.52%
$20.23
NOK
-1.31%
$5.25
EOSE
+23.37%
$17.05
BMNR
+8.34%
$56.85
PLTR
+1.00%
$177.21
RMBL
+60.50%
$3.21
ADAP
-2.59%
$0.18
EPWK
-8.00%
$0.08
BULL
+2.98%
$11.74
ADD
-25.47%
$0.05
AAPL
+0.97%
$247.66
AMZN
+1.71%
$220.07
WULF
+3.62%
$14.00
XCH
+103.41%
$1.68
T
-1.08%
$25.59
HPE
+1.63%
$24.80
RF
+1.65%
$24.56
NB
+8.95%
$11.32
SRM
+53.27%
$10.30
BTG
+4.52%
$5.31
CLSK
+3.94%
$20.04
GDXD
-13.62%
$0.73
BAC
+0.43%
$48.86
QSI
+24.55%
$2.08
KDP
+2.32%
$26.42
RGTZ
-50.00%
$9.30
VALE
+2.41%
$11.01
SMR
+14.72%
$45.02
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
SLB
+1.73%
$32.27
ORCL
-1.34%
$292.95
ABEV
+1.42%
$2.14
BE
+26.52%
$109.91
WLGS
-5.57%
$0.04
TMC
+20.31%
$10.69
HOOD
+1.23%
$140.68
TMQ
+10.62%
$6.56
GRAB
+1.19%
$5.93
KDLY
-7.21%
$0.87
GGB
+2.85%
$3.24
ETWO
0.00%
$3.30
VHAI
+66.66%
$0.00
YYAI
-10.47%
$0.17
BURU
+7.74%
$0.51
CGBS
-39.47%
$0.03
ELBM
+325.45%
$7.02
PLUG
+14.03%
$3.90
RGTI
+25.02%
$54.91
GWH
+117.54%
$9.05
BITF
+28.33%
$5.39
NVDA
+2.81%
$188.32
NVTS
+21.14%
$9.97
ASST
-30.54%
$1.08
IONZ
-32.55%
$2.29
BYND
-48.50%
$1.03
INTC
+2.33%
$37.22
JOBY
+3.00%
$16.77
DNN
+6.94%
$3.08
GPUS
-10.39%
$0.43
CAN
+39.44%
$1.52
QBTS
+23.01%
$40.61
TSLA
+5.41%
$435.90
BBD
+0.98%
$3.09
F
+1.13%
$11.54
CLF
+4.93%
$13.83
AXDX
-61.36%
$0.03
NIO
+7.00%
$7.18
QS
+15.57%
$16.98
AMD
+0.70%
$216.42
SOFI
+3.62%
$27.14
CRML
+55.40%
$23.28
ETHD
-12.82%
$3.33
CIFR
+19.85%
$20.34
ACHR
+6.68%
$12.77
RXRX
+3.94%
$5.53
APLD
+0.73%
$34.24
SOUN
+10.25%
$19.14
DFLI
+44.03%
$1.57
TLRY
-1.74%
$1.69
BTBT
+6.38%
$4.00
NAK
+31.03%
$2.66
LAES
+13.30%
$6.13
ONDS
+17.24%
$10.81
DVLT
-10.52%
$1.70
RR
+8.95%
$6.45
MP
+21.34%
$95.06
USAR
+18.61%
$38.68
IONQ
+16.19%
$82.09
IREN
+7.31%
$64.14
AVGO
+9.87%
$356.70
UAMY
+36.85%
$16.71
ABAT
+36.59%
$9.22
PFE
-0.20%
$24.73
SNAP
+3.47%
$8.05
NAKA
-1.56%
$0.85
RIG
+3.89%
$3.20
AAL
+1.90%
$11.74
QUBT
+12.85%
$21.46
UUUU
+16.86%
$23.77
MARA
+8.52%
$20.23
NOK
-1.31%
$5.25
EOSE
+23.37%
$17.05
BMNR
+8.34%
$56.85
PLTR
+1.00%
$177.21
RMBL
+60.50%
$3.21
ADAP
-2.59%
$0.18
EPWK
-8.00%
$0.08
BULL
+2.98%
$11.74
ADD
-25.47%
$0.05
AAPL
+0.97%
$247.66
AMZN
+1.71%
$220.07
WULF
+3.62%
$14.00
XCH
+103.41%
$1.68
T
-1.08%
$25.59
HPE
+1.63%
$24.80
RF
+1.65%
$24.56
NB
+8.95%
$11.32
SRM
+53.27%
$10.30
BTG
+4.52%
$5.31
CLSK
+3.94%
$20.04
GDXD
-13.62%
$0.73
BAC
+0.43%
$48.86
QSI
+24.55%
$2.08
KDP
+2.32%
$26.42
RGTZ
-50.00%
$9.30
VALE
+2.41%
$11.01
SMR
+14.72%
$45.02
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
SLB
+1.73%
$32.27
ORCL
-1.34%
$292.95
ABEV
+1.42%
$2.14
BE
+26.52%
$109.91
WLGS
-5.57%
$0.04
TMC
+20.31%
$10.69
HOOD
+1.23%
$140.68
TMQ
+10.62%
$6.56
GRAB
+1.19%
$5.93
KDLY
-7.21%
$0.87
GGB
+2.85%
$3.24
ETWO
0.00%
$3.30
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.